Kodiak Sciences reports Q4 net loss of $44.1M, cash $168.1M; pipeline trials on track

Kodiak Sciences Inc.

Cash and equivalents $168.1M at Dec 31, 2024; expected to fund operations into 2026.
Q4 2024 net loss $44.1M ($0.84/sh) vs $59.5M ($1.13/sh) in Q4 2023; R&D expenses $31.8M.
Tarcocimab Phase 3 GLOW2 (diabetic retinopathy) enrollment complete; topline data targeted 1Q2026.
Tarcocimab & KSI-501 Phase 3 DAYBREAK (wet AMD) enrollment complete; topline data targeted 2Q2026.
KSI-101 granted FDA Orphan Drug Designation; pivotal study initiation expected 2Q2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.